HIV/antiretroviral therapy-related lipodystrophy syndrome (HALS) is associated with higher RBP4 and lower omentin in plasma

Clinical Microbiology and Infection

Volumn 21, Issue 7, 2015, Pages 711.e1-711.e8

  Peraire, J ^a   Lopez Dupla M ^a   Alba, V ^a   Beltran Debon R ^a   Martinez, E ^b   Domingo, P ^c   Asensi, V ^d   Leal, M ^e   Vilades C ^a   Inza, M I ^a   Escote X ^a,f   Arnedo, M ^b   Mateo, G ^c   Valle Garay, E ^d   Ferrando Martinez, S ^e   Veloso, S ^a   Vendrell, J ^a,f   Gatell, J Ma ^b   Vidal, F ^a   Aguilar, Alba ^a   Aguilar, Àngel ^a   Alibalic, Ajla ^a   Balañá, Josep ^a   Ceausu, Andra ^a   Garcia, Manel ^a   Guillén, Gilsy ^a   Milián, Marta ^a   Muñoz, Glòria ^a   Vargas, Montserrat ^a   Fontanet, Àngels ^c   Gutiérrez, Mar ^c   Muñoz, Jessica ^c   Sambeat, Ma Antònia ^c   Egaña Gorroño, Lander ^g   more..

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

Author keywords

Apelin; HALS; HIV; Omentin; RBP4; Vaspin; Visfatin

Indexed keywords

ADIPOCYTOKINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APELIN; APELIN RECEPTOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RETINOL BINDING PROTEIN 4; VASPIN; ANTIRETROVIRUS AGENT; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN; PLASMA RETINOL BINDING PROTEIN; RBP4 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CHI SQUARE TEST; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHENOTYPE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AGED; BLOOD; CASE CONTROL STUDY; CHEMISTRY; CLINICAL TRIAL; COMPLICATION; GENETIC POLYMORPHISM; GENETICS; HIV INFECTIONS; MIDDLE AGED; PATHOLOGY; PLASMA; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; GPI-LINKED PROTEINS; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LECTINS; MALE; MIDDLE AGED; PLASMA; POLYMORPHISM, GENETIC; RETINOL-BINDING PROTEINS, PLASMA; YOUNG ADULT;

EID: 84930807339     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.04.002     Document Type: Article

References (41)

1. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
2. Johnson J.A., Albu J.B., Engelson E.S., Fried S.K., Inada Y., Ionescu G., et al. Increased systemic and adipose tissue cytokines in patients with HIV-1-associated lipodystrophy. Am J Physiol Metab 2004, 286:E261-E271.
3. Diaz-Delfin J., Gutiérrez MdM., Gallego-Escuredo J.M., Domingo J.C., Gracia Mateo M., Villarroya F., et al. Effects of nevirapine and efavirenz on human adipocyte differentiation gene expression, and release of adipokines and cytokines. Antivir Res 2011, 91:112-119.
4. Palios J., Kadoglou N.P., Lampropoulos S. The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: the emerging role of adipokines. Exp Diabetes Res 2012, 2012:103063.
5. Escoté X., Miranda M., Veloso S., Domingo P., Alonso-Villaverde C., Peraire J., et al. Lipodystrophy and insulin resistance in combination antiretroviral treate HIV-1-infected patients: implication of resistin. JAcquir Immune Defic Syndr 2011, 57:16-23.
6. Escoté X., Megia A., López-Dupla M., Miranda M., Veloso S., Alba V., et al. Astudy of fatty acid binding protein 4 in HIV-1 infection and in combination antiretroviral therapy-related metabolic disturbances and lipodystrophy. HIV Med 2011, 12:428-437.
7. Ceperuelo-Mallafré V., Escoté X., Viladés C., Peraire J., Domingo P., Solano E., et al. Zinc alpha-2 glycoprotein is implicated in dyslipidaemia in HIV-1-infected patients treated with antiretroviral drugs. HIV Med 2012, 13:297-303.
8. Veloso S., Escoté X., Ceperuelo-Mallafré V., López-Dupla M., Peraire J., Viladés C., et al. Leptin and adiponectin, but not IL18, are related with insulin resistance in treated HIV-1-infected patients with lipodystrophy. Cytokine 2012, 58:253-260.
9. Sahin-Efe A., Katsikeris F., Mantzoros C.S. Advances in adipokines. Metabolism 2012, 61:1659-1665.
10. Tsiodras S., Perelas A., Wanke C., Mantzoros C.S. The HIV-1/HAART associated metabolic syndrome-novel adipokines, molecular associations and therapeutic implications. JInfect 2010, 61:101-113.
11. Al-Suhaimi E.A., Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res 2013, 18:12.
12. Koethe J.R., Hulgan T., Niswender K. Adipose tissue and immune function: a review of evidence relevant to HIV infection. JInfect Dis 2013, 208:1194-1201.
13. Hendel H., Winkler C., An P., Roemer-Binns E., Nelson G., Haumont P., et al. Validation of genetic case-control studies in AIDS and application to the CX3CR1 polymorphism. JAcquir Immune Defic Syndr 2001, 15:507-511.
14. Carr A., Samaras K., Thorisdottir A., Kaufmann G.R., Chisholm D.J., Cooper D.A. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-assocated lipodystrophy, hyperlipidaemiia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
15. Viladés C., Escoté X., López-Dupla M., Martinez E., Domingo P., Asensi V., et al. Involvement of LPS-LBP-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-related lipodystrophy síndrome. JAntimicrob Chemother 2014, 69:1653-1659.
16. Villarroya F., Domingo P., Giralt M. Lipodystrophy in HIV-1 infected patients: lessons for obesity research. Int J Obes 2007, 31:1763-1776.
17. Shibata R., Brechi N., Takahashi R., Terakura Y., Ohashi K., Ikeda N., et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr 2012, 4:37.
18. Jialal I., Devaraj S., Kaur H., Adams-Huet B., Bremer A.A. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. JClin Endocrinol Metab 2013, 98:E514-E517.
19. Greulich S., Chen W.J.Y., Maxhera B., Rijzewijk L.J., van der Meer R.W., Jonker J.T., et al. Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and invitro studies. PLoS One 2013, 8:e59697.
20. Li X.P., Zeng S., Wang M., Wu X.P., Liao E.Y. Relationship between serum omentin-1, body fat mass and bone mineral density in healthy Chinese male adults in Changsha area. JEndocrinol Invest 2014, 37:991-1000.
21. Kotnik P., Fischer-Posovszky P., Wabistch M. RBP4: a controversial adipokine. Eur J Endocrinol 2011, 165:703-711.
22. Yang Q., Graham T.E., Mody N., Preitner F., Peroni O.D., Zabolotny J.M., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436:356-362.
23. Schindler K., Haider D., Woltz M., Rieger A., Gmeinhart B., Luger A., et al. Impact of antiretroviral therapy on visfatin and retinol-binding protein-4 in HIV-infected subjects. Eur J Clin Invest 2006, 36:640-646.
24. Haider D.G., Schindler K., Mittermayer F., Müller M., Nowotny P., Rieger A., et al. Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients. Clin Pharmacol Ther 2007, 81:580-585.
25. Jeong S.J., Chin B.S., Chae Y.T., Jin S.J., Ku N.S., Baek J.H., et al. Serum retinol binding protein-4 levels are increased in HIV-infected subjects with metabolic syndrome receiving highly active antiretroviral therapy. Yonsei Med J 2012, 53:1211-1215.
26. Hung Y.P., Lee N.Y., Lin S.H., Chang H.C., Wu C.J., Chang C.M., et al. Effects of PPARγ and RBP4 gene variants on metabolic syndrome in HIV-infected patients with anti-retroviral therapy. PLoS One 2012, 7:e49102.
27. Han S.H., Chin B.S., Lee H.S., Jeong S.J., Choi H.K., Kim C.O., et al. Serum retinol-binding protein-4 correlated with obesity, insulin resistance, and dyslipidemia in HIV-infected subjects receiving highly active antiretroviral therapy. Metabolism 2009, 58:1523-1529.
28. Theodoridou K., Margei A., Spolou V., Bathrellou I., Skevaki C., Chrousos G.P., et al. Non-traditional adipokines in pediatric HIV-related lipodystrophy: a-FABP as a biomarker of central fat accumulation. Scand J Clin Lab Med 2014, 74:67-73.
29. Marill J., Idres N., Capron C.C., Nguyen E., Chabot G.G. Retinoic acid metabolism and mechanism of action: a review. Curr Drug Metab 2003, 4:1-10.
30. Ferré P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004, 53(Suppl.1):S43-S50.
31. Castan-Laurell I., Dray C., Attané C., Duparc T., Knauf C., Valet P. Apelin. Diabetes, and obesity. Endocrine 2011, 40:1-9.
32. Castan-Laurell I., Dray C., Knauf C., Kunduzova O., Valet P. Apelin, a promising target for type 2 diabetes treatment?. Trends Endocrinol Metab 2012, 23:234-241.
33. Zhou N., Zhang X., Fan X., Argyris E., Fang J., Acheampong E., et al. The N-terminal domain of APJ, a CNS-based coreceptor for HIV-1, is essential for its receptor function and coreceptor activity. Virology 2003, 317:84-94.
34. Zou M.X., Liu H.Y., Haraguchi Y., Soda Y., Tatemoto K., Hoshino H. Apelin peptides block the entry of human immunodeficiency virus (HIV). FEBS Lett 2000, 473:15-18.
35. Hida K., Wada J., Eguchi J., Zhang H., Baba M., Seida A., et al. Visceral adipose tissue-derived serina protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005, 102:10610-10615.
36. Blüher M. Vaspin in obesity and diabetes: pathophysiological and clinical significance. Endocrine 2012, 41:176-182.
37. Chang Y.H., Chang D.M., Lin K.C., Shin S.J., Lee Y.J. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011, 27:515-527.
38. Stastny J., Bienertova-Vasku J., Vasku A. Visfatin and its role in obesity development. Diabetes Metab Syndr 2012, 6:120-124.
39. Parfieniuk-Kowerda A., Czaban S.L., Grzeszczuk A., Jaroszewicz J., Flisiak R. Assessment of serum IGF-1 and adipokines related to metabolic dysfunction in HIV-infected adults. Cytokine 2013, 64:97-102.
40. Zhang H.S., Sang W.W., Wang Y.O., Liu W. Nicotinamide phosphoribosyltransferase/sirtuin 1 pathway is involved in human immunodeficiency virus type 1 Tat-mediated long terminal repeat transactivation. JCell Biochem 2010, 110:1464-1470.
41. Van den Bergh R., Florence E., Vlieghe E., Boonefaes T., Grooten J., Houthuys E., et al. Transcriptome analysis of monocyte-HIV interactions. Retrovirology 2010, 7:53.